Amylyx Pharmaceuticals (AMLX) Operating Margin (2021 - 2024)
Amylyx Pharmaceuticals' (AMLX) quarterly Operating Margin came in at 6392.14% in Q4 2024, up 639036.0% year-on-year from N/an in Q1 2024, and up 135.15% quarter-over-quarter from 18187.74% in Q3 2024.
Amylyx Pharmaceuticals (AMLX) Operating Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' Operating Margin history runs 4 years deep, the most recent figure standing at 6392.14% for Q4 2024.
- On a quarterly basis, Operating Margin rose 639036.0% year-over-year to 6392.14% in Q4 2024; TTM through Sep 2025 was 24739.15%, a 2487623.0% increase from a year earlier, with the FY2024 full-year figure at 360.1%, down 37029.0% from the prior year.
- Operating Margin rose to 6392.14% in Q4 2024 per AMLX's latest filing, from 18187.74% in the prior quarter.
- Across five years, Operating Margin topped out at 6392.14% in Q4 2024 and bottomed at 18187.74% in Q3 2024.
- The 4-year median for Operating Margin is 137.78% (2024), against an average of 3949.77%.
- Across the five-year window, Operating Margin jumped 1586779 bps in 2023 and plunged 1820597 bps in 2024, its largest moves.
- Year by year, Operating Margin stood at 8041.4% in 2021, then jumped by 97 bps to 203.76% in 2022, then soared by 101 bps to 1.78% in 2023, then soared by 358339 bps to 6392.14% in 2024.
- Per Business Quant, the three latest AMLX Operating Margin figures stand at 6392.14% (Q4 2024), 18187.74% (Q3 2024), and 7457.09% (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,392.14% |
| Sep 30, 2024 | -18,187.74% |
| Jun 30, 2024 | -7,457.09% |
| Mar 31, 2024 | -137.78% |
| Dec 31, 2023 | 1.78% |
| Sep 30, 2023 | 18.23% |
| Jun 30, 2023 | 20.57% |
| Mar 31, 2023 | -2.87% |
| Dec 31, 2022 | -203.76% |
| Sep 30, 2022 | -15,849.57% |
| Sep 30, 2021 | -8,041.40% |